Actinium Pharmaceuticals, Inc.
Simbol: ATNM
AMEX
8.75
USDTržna cena danes
-5.2530
Razmerje P/E
0.0000
Razmerje PEG
260.61M
Kapaciteta MRK
- 0.00%
Donos DIV
Actinium Pharmaceuticals, Inc. (ATNM) Finančni izkazi
Bilanca stanja
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 334.99 | 76.7 | 108.9 | 77.8 | ||||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.net-receivables | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.other-current-assets | 9.78 | 1.6 | 2 | 1.9 | ||||||||||||||||||
balance-sheet.row.total-current-assets | 344.77 | 78.3 | 110.9 | 79.7 | ||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 11.78 | 2.9 | 2.9 | 0.6 | ||||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.long-term-investments | 1.25 | 0.3 | 0.3 | 0 | ||||||||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 0 | 0 | -0.6 | ||||||||||||||||||
balance-sheet.row.total-non-current-assets | 13.02 | 3.2 | 3.3 | 0.6 | ||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.total-assets | 357.79 | 81.4 | 114.2 | 80.4 | ||||||||||||||||||
balance-sheet.row.account-payables | 32.25 | 8 | 10.1 | 5.5 | ||||||||||||||||||
balance-sheet.row.short-term-debt | 2.13 | 0.5 | 0.5 | 0.3 | ||||||||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.long-term-debt-total | 6.51 | 1.6 | 2.1 | 0 | ||||||||||||||||||
Deferred Revenue Non Current | 140 | 35 | 35 | 0 | ||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | -106.57 | - | - | - | ||||||||||||||||||
balance-sheet.row.other-current-liab | -104.46 | -35 | -35 | 0 | ||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 146.51 | 36.6 | 37.1 | 0 | ||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 7.55 | 1.6 | 2.6 | 0.3 | ||||||||||||||||||
balance-sheet.row.total-liab | 180.9 | 45.1 | 47.7 | 6.8 | ||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.common-stock | 0.11 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.retained-earnings | -1327.08 | -337.6 | -288.8 | -255.7 | ||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 1503.86 | 373.9 | 355.2 | 329.3 | ||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 176.9 | 36.4 | 66.5 | 73.5 | ||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 357.79 | 81.4 | 114.2 | 80.4 | ||||||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.total-equity | 176.9 | 36.4 | 66.5 | 73.5 | ||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 357.79 | - | - | - | ||||||||||||||||||
Total Investments | 1.25 | 0.3 | 0.3 | 0 | ||||||||||||||||||
balance-sheet.row.total-debt | 8.64 | 2.1 | 2.6 | 0.3 | ||||||||||||||||||
balance-sheet.row.net-debt | -326.35 | -74.6 | -106.3 | -77.5 |
Izkaz denarnih tokov
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -46.45 | -48.8 | -33 | -24.8 | ||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0.82 | 0.8 | 0.7 | 0.5 | ||||||||||||||||||
cash-flows.row.deferred-income-tax | -3.47 | 2.2 | 0.4 | -1.5 | ||||||||||||||||||
cash-flows.row.stock-based-compensation | 4.23 | 3.8 | 2.8 | 1.7 | ||||||||||||||||||
cash-flows.row.change-in-working-capital | 1.77 | -3.1 | 38.2 | 1.7 | ||||||||||||||||||
cash-flows.row.account-receivables | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.account-payables | 0.15 | -2.2 | 4.6 | 1.2 | ||||||||||||||||||
cash-flows.row.other-working-capital | 1.61 | -1 | 33.6 | 0.5 | ||||||||||||||||||
cash-flows.row.other-non-cash-items | 5.72 | -2.2 | -0.4 | 1.5 | ||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -39.63 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -0.09 | -0.2 | -0.4 | -0.1 | ||||||||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -0.09 | -0.2 | -0.4 | -0.1 | ||||||||||||||||||
cash-flows.row.debt-repayment | -0.01 | 0 | 0 | -0.1 | ||||||||||||||||||
cash-flows.row.common-stock-issued | 28.61 | 14.9 | 23.2 | 35.3 | ||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.other-financing-activites | 19.08 | 0.3 | 23.1 | 0 | ||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 28.87 | 14.9 | 23.1 | 35.2 | ||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.net-change-in-cash | -10.86 | -32.6 | 31.4 | 14.2 | ||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 335.61 | 76.7 | 109.6 | 78.2 | ||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 346.46 | 109.3 | 78.2 | 64 | ||||||||||||||||||
cash-flows.row.operating-cash-flow | -39.63 | -47.3 | 8.6 | -20.9 | ||||||||||||||||||
cash-flows.row.capital-expenditure | -0.09 | -0.2 | -0.4 | -0.1 | ||||||||||||||||||
cash-flows.row.free-cash-flow | -39.72 | -47.5 | 8.3 | -21 |
Vrstica izkaza poslovnega izida
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0.08 | 0.1 | 1 | 1.1 | ||||||||||||||||||
income-statement-row.row.cost-of-revenue | 0.82 | 0.8 | 0.7 | 0.5 | ||||||||||||||||||
income-statement-row.row.gross-profit | -0.74 | -0.7 | 0.3 | 0.6 | ||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||||
income-statement-row.row.research-development | 37.04 | - | - | - | ||||||||||||||||||
income-statement-row.row.selling-general-administrative | 12.56 | - | - | - | ||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | -0.22 | - | - | - | ||||||||||||||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | ||||||||||||||||||
income-statement-row.row.operating-expenses | 49.6 | 51.2 | 35.1 | 26.1 | ||||||||||||||||||
income-statement-row.row.cost-and-expenses | 50.01 | 52 | 35.1 | 26.1 | ||||||||||||||||||
income-statement-row.row.interest-income | 3.48 | 3.1 | 1.1 | 0.2 | ||||||||||||||||||
income-statement-row.row.interest-expense | 0.55 | 0 | -1.1 | 0 | ||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | -0.22 | - | - | - | ||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 3.48 | 3.1 | 1.1 | 0.2 | ||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | ||||||||||||||||||
income-statement-row.row.total-operating-expenses | 3.48 | 3.1 | 1.1 | 0.2 | ||||||||||||||||||
income-statement-row.row.interest-expense | 0.55 | 0 | -1.1 | 0 | ||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0.82 | 0.8 | 0.7 | 0.5 | ||||||||||||||||||
income-statement-row.row.ebitda-caps | -49.11 | - | - | - | ||||||||||||||||||
income-statement-row.row.operating-income | -49.93 | -51.9 | -34.1 | -25 | ||||||||||||||||||
income-statement-row.row.income-before-tax | -46.45 | -48.8 | -33 | -24.8 | ||||||||||||||||||
income-statement-row.row.income-tax-expense | 0.55 | 0 | -1.1 | -0.2 | ||||||||||||||||||
income-statement-row.row.net-income | -46.45 | -48.8 | -31.9 | -24.6 |
Pogosto zastavljeno vprašanje
Kaj je Actinium Pharmaceuticals, Inc. (ATNM) skupna sredstva?
Actinium Pharmaceuticals, Inc. (ATNM) skupna sredstva so 81445000.000.
Kakšen je letni prihodek podjetja?
Letni prihodki so 81000.000.
Kolikšna je stopnja dobička podjetja?
Dobiček podjetja je -9.173.
Kakšen je prosti denarni tok podjetja?
Prosti denarni tok je -1.424.
Kolikšna je neto stopnja dobička podjetja?
Čista stopnja dobička je -573.469.
Kolikšni so skupni prihodki podjetja?
Celotni prihodki so -616.457.
Kaj je Actinium Pharmaceuticals, Inc. (ATNM) čisti dobiček (čisti dobiček)?
Čisti dobiček (čisti prihodek) je -48818000.000.
Kolikšen je skupni dolg podjetja?
Skupni dolg je 2113000.000.
Kolikšni so stroški poslovanja?
Stroški poslovanja so 51211000.000.
Kolikšno je število denarnih sredstev podjetja?
Denarna sredstva podjetja so 84057000.000.